Pharmaceutical Giants Gain $440B After Dodging Trump’s Tariff and Pricing Bullet
The trade war medicine went down easier than expected — at least for drugmakers. The top-30 life sciences firms added $440B in value last week as investors realized “Trump’s tariff and [pricing] policies were unlikely to impact pharma nearly as badly as feared,” according to Stifel’s Tim Opler. This shift comes as Pfizer’sPFE recent deal with the White House showcased that there was room to bargain and that profit cuts would be limited.
- Pfizer won three years of tariff relief by accepting “most favored nation” pricing for Medicaid drugs — a minor hit since its Medicaid rates already rank among the lowest.
- Pfizer, RocheRHHBY, and AstraZenecaAZN plan to invest $70B, $50B, and $50B, respectively, in US manufacturing after Trump said domestic investors would dodge tariffs.
The honeymoon might be short-lived: While Christian Koch of Bellevue Asset Management predicts the agreement “signals an export of US-style free pricing to the developed world,” analysts at Capital Alpha Partners warn that “drug pricing and tariff risk remain.” Gilead Sciences faces a tougher road since Medicaid covers ~40% of HIV patients and represents 70% of the company’s revenue stream from HIV treatments. Raymond James analyst Chris Meekins cautioned that “more actions are likely to come” from the White House, suggesting pharma’s reprieve could prove temporary as Trump extracts additional concessions.